Trial Profile
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naive Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MARAVIBOOST
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database).
- 23 Jun 2012 Status changed from active, no longer recruiting to completed, according to the European Clinical Trials Database.
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.